So much of what we know about heart health is based on male models. Classic heart attack symptoms describe the experiences of men, drugs were developed largely by men for men—even in research, mouse models were male. But in recent years, our understanding of women's cardiac health has expanded, and critically, we have learned that we cannot simply apply male models to female patients. As one of our guests says, "women are not small men." For American Heart Month, join us for a heart-to-heart with members of the SNMMI Cardiovascular Council as they discuss how nuclear cardiology is providing new insight into women's heart health. Listen here or wherever you stream your podcasts. 

This episode of the SNMMI Podcast is sponsored by GE Healthcare.

Important Safety Information – VIZAMYL

PRODUCT INDICATIONS AND USE

VIZAMYL™ (flutemetamol F 18 injection) is indicated for positron-emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:

· Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline

· Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing of information of the therapeutic products.

CONTRAINDICATIONS

VIZAMYL is contraindicated in patients with a history of hypersensitivity reaction to VIZAMYL or polysorbate 80.

ADVERSE REACTIONS

The most commonly reported adverse reactions in clinical trials were flushing (2 %), increased blood pressure (2 %), headache (1 %), nausea and dizziness (1 %). Postmarketing experience included anaphylactic reactions. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Prior to VIZAMYL administration, please read the full Prescribing Information for additional Important Safety Information: https://gehealthcare.com/vizamyl-pi